The Food and Drug Administration issued a Refusal to File letter to Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) for its New Drug Application for Firdapse. Shares of the biopharmaceutical tumbled 71 cents to $1.14.
Catalyst Pharmaceuticals receives Refusal to File letter
February 17, 2016 at 12:36 PM EST
